Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Bayer Titan Pharmaceuticals |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00206687 |
The purpose of the study is to explore the safety, tolerability and efficacy of Spheramine (cultured human retinal pigment epithelial cells on microcarriers) in Parkinson's Disease patients with advanced disease who have insufficient symptom control by optimum oral medication. Patients are randomized to receive Spheramine injections into both hemispheres or a sham surgical procedure in a ratio of 1:1. A three month pretreatment period must be completed prior to surgery. Time to endpoint is 24 months.
Condition | Intervention | Phase |
---|---|---|
Parkinson Disease |
Procedure: Spheramine (BAY86-5280) Procedure: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease |
Estimated Enrollment: | 68 |
Study Start Date: | January 2003 |
Estimated Study Completion Date: | June 2012 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Procedure: Spheramine (BAY86-5280)
Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
|
Arm 2: Sham Comparator |
Procedure: Placebo
Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
|
This study has previously been posted by Berlex, Inc. and Schering AG, Germany. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors of the trial.
Ages Eligible for Study: | 30 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
Los Angeles, California, United States, 90095 | |
United States, Florida | |
Tampa, Florida, United States, 33606 | |
United States, Georgia | |
Atlanta, Georgia, United States, 30322 | |
United States, Illinois | |
Chicago, Illinois, United States, 60612 | |
United States, Kansas | |
Kansas City, Kansas, United States, 66160 | |
United States, Massachusetts | |
Boston, Massachusetts, United States, 02118-2394 | |
United States, New York | |
New York, New York, United States, 10029 | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Texas | |
Houston, Texas, United States, 77030 | |
Germany | |
Hamburg, Germany, 22307 | |
Germany, Hessen | |
Marburg, Hessen, Germany, 35043 | |
Germany, Saarland | |
Homburg, Saarland, Germany, 66421 | |
Germany, Sachsen | |
Dresden, Sachsen, Germany, 01307 | |
Spain | |
Barcelona, Spain, 08036 |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Schering Pharma AG ( Therapeutic Area Head ) |
Study ID Numbers: | 91039, 305405 |
Study First Received: | September 13, 2005 |
Last Updated: | September 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00206687 History of Changes |
Health Authority: | United States: Food and Drug Administration; Germany: Federal Institute for Drugs and Medical Devices |
Ganglion Cysts Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
Movement Disorders Parkinson Disease Nervous System Diseases Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |